|

Ipilimumab 1mg/kg Nivolumab 480mg and relatlimab 160mg Clinical Trials

1 actively recruiting trial

Also known as: Arm B

Pipeline

Phase 2: 1

Top Sponsors

  • Melanoma Institute Australia1

Indications

  • Mucosal Melanoma1
  • Cutaneous Melanoma1
  • Cancer1

Other1 trial

Neo IRENIE (NEOadjuvant Ipilimumab, RElatlimab, NIvolumab Evaluation)
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.